Aadi Bioscience, Inc.

NasdaqCM:AADI Voorraadrapport

Marktkapitalisatie: US$56.2m

Aadi Bioscience Beheer

Beheer criteriumcontroles 2/4

De CEO Aadi Bioscience is Dave Lennon, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.14M, bestaande uit 7.5% salaris en 92.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.093% van de aandelen van het bedrijf, ter waarde $ 52.14K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 3.3 jaar.

Belangrijke informatie

Dave Lennon

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris7.5%
Dienstverband CEO1.1yrs
Eigendom CEO0.09%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur3.3yrs

Recente managementupdates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Analyse CEO-vergoeding

Hoe is Dave Lennon's beloning veranderd ten opzichte van Aadi Bioscience's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$160k

-US$66m

Compensatie versus markt: De totale vergoeding ($USD 2.14M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Dave te vergelijken met de prestaties van het bedrijf.

CEO

Dave Lennon (53 yo)

1.1yrs

Tenure

US$2,135,687

Compensatie

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Scott Giacobello
CFO, Treasurer3yrsUS$1.97m0%
$ 0
Stephen Rodin
Senior VP of Legal & General Counsel2.8yrsgeen gegevensgeen gegevens
Raymond Steitz
Senior VP of Human Resources & Chief Human Resources Officer2.4yrsgeen gegevensgeen gegevens
Bryan Ball
Chief Technical Operations Officer2.3yrsgeen gegevens0.41%
$ 228.0k

2.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AADI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Caley Castelein
Independent Chairman of the Board3.3yrsUS$258.91k0.080%
$ 44.9k
Emma Reeve
Independent Director3.2yrsUS$240.91k0%
$ 0
Anupam Dalal
Independent Director3.3yrsUS$235.91k0.0046%
$ 2.6k
Karin Hehenberger
Independent Director3.3yrsUS$227.41k0%
$ 0
Richard Maroun
Independent Director7.8yrsUS$240.91k0%
$ 0
Mohammad Hirmand
Independent Director1.7yrsUS$345.60k0%
$ 0
Behzad Aghazadeh
Independent Director3.3yrsUS$225.41k0%
$ 0

3.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AADI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).